BioCentury
ARTICLE | Clinical News

Genasense oblimersen sodium injection: Additional Phase III data

May 30, 2011 7:00 AM UTC

Additional data from the double-blind, international Phase III AGENDA trial in 314 patients showed that IV Genasense plus dacarbazine missed the co-primary endpoint of significantly improving median O...